Concepedia

Author

Mark T. Brown

Pfizer (United States)ORCID

Also Known As

M Brown, M T Brown, M. Brown, M. T. Brown, M.T. Brown, Mark Brown, Mark T Brown, Mark T. Brown, Mark T. Brown

73

Publications

3.7K

Citations

28

H-Index

72

Concepts

All Affiliations

Pfizer (United States)Duke Medical CenterEli Lilly (United States)Northwestern UniversityDuke University Hospital
MT

About

Mark T. Brown is an author at Pfizer (United States) specializing in medicine, health sciences, and orthopaedics.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

13

14

703

2

Health Sciences

8

8

585

3

Anatomy

4

4

106

4

Arts

1

1

14

5

Social Sciences

1

1

23

Mark T. Brown

×

40

Publications

3.4K

Citations

26

H-Index

YearCitations

Complications of the COX-2 Inhibitors Parecoxib and Valdecoxib after Cardiac Surgery

Nancy A. Nussmeier, Andrew Whelton, Mark T. Brown,

New England Journal of Medicine

2005

1.1K

Tanezumab Reduces Osteoarthritic Knee Pain: Results of a Randomized, Double-Blind, Placebo-Controlled Phase III Trial

Mark T. Brown, Frederick T. Murphy, David Radin,

Journal of Pain

2012

194

Iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with recurrent malignant gliomas: phase I trial results.

Darell D. Bigner, Mark T. Brown, Allan H. Friedman,

Journal of Clinical Oncology

1998

194

Safety and Efficacy of the Cyclooxygenase-2 Inhibitors Parecoxib and Valdecoxib after Noncardiac Surgery

Nancy A. Nussmeier, Andrew Whelton, Mark T. Brown,

Anesthesiology

2006

160

Efficacy and safety of tanezumab monotherapy or combined with non-steroidal anti-inflammatory drugs in the treatment of knee or hip osteoarthritis pain

Thomas J. Schnitzer, Evan F. Ekman, Egilius L.H. Spierings,

Annals of the Rheumatic Diseases

2014

147

A phase III placebo- and oxycodone-controlled study of tanezumab in adults with osteoarthritis pain of the hip or knee

Egilius L.H. Spierings, James Fidelholtz, G Wolfram,

Pain

2013

127

Rehabilitation versus surgical reconstruction for non-acute anterior cruciate ligament injury (ACL SNNAP): a pragmatic randomised controlled trial

David Beard, Loretta Davies, Jonathan Cook,

The Lancet

2022

119

Cyclophosphamide, doxorubicin, vincristine, and prednisone for primary central nervous system lymphoma

D. H. Lachance, David M. Brizel, Jon P. Gockerman,

Neurology

1994

99

Intrathecal 131I-labeled antitenascin monoclonal antibody 81C6 treatment of patients with leptomeningeal neoplasms or primary brain tumor resection cavities with subarachnoid communication: phase I trial results.

Mark T. Brown, R. Edward Coleman, Allan H. Friedman,

PubMed

1996

99

Efficacy and safety of tanezumab added on to diclofenac sustained release in patients with knee or hip osteoarthritis: a double-blind, placebo-controlled, parallel-group, multicentre phase III randomised clinical trial

Andra Bălănescu, Eugen Feist, G Wolfram,

Annals of the Rheumatic Diseases

2013

89

Page 1